{"id":"NCT02904902","sponsor":"AbbVie","briefTitle":"Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa","officialTitle":"A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-06","primaryCompletion":"2017-09-01","completion":"2019-05-30","firstPosted":"2016-09-19","resultsPosted":"2019-02-27","lastUpdate":"2020-05-12"},"enrollment":15,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hidradenitis Suppurativa"],"interventions":[{"type":"DRUG","name":"adalimumab","otherNames":["Humira"]}],"arms":[{"label":"Adalimumab","type":"EXPERIMENTAL"}],"summary":"This study investigates efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with moderate to severe hidradenitis suppurativa (HS).","primaryOutcome":{"measure":"Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Adalimumab","deltaMin":86.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":15},"commonTop":["Influenza","Nasopharyngitis","Periodontitis","Constipation","Dental caries"]}}